[HTML][HTML] Monoclonal antibody-based therapies for myasthenia gravis
S Alabbad, M AlGaeed, P Sikorski, HJ Kaminski - BioDrugs, 2020 - Springer
Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder that produces disabling
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
Monoclonal Antibody‑Based Therapies for Myasthenia Gravis
S Alabbad, M AlGaeed, P Sikorski, HJ Kaminski - BioDrugs, 2020 - search.proquest.com
Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder that produces disabling
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
Monoclonal Antibody-Based Therapies for Myasthenia Gravis
S Alabbad, M AlGaeed, P Sikorski… - … and gene therapy, 2020 - pubmed.ncbi.nlm.nih.gov
Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder that produces disabling
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
Monoclonal Antibody-Based Therapies for Myasthenia Gravis.
S Alabbad, M AlGaeed, P Sikorski… - … and Gene Therapy, 2020 - europepmc.org
Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder that produces disabling
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
[PDF][PDF] Monoclonal Antibody‑Based Therapies for Myasthenia Gravis
S Alabbad, M AlGaeed, P Sikorski, HJ Kaminski - BioDrugs, 2020 - academia.edu
Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder that produces disabling
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
[HTML][HTML] Monoclonal Antibody-Based Therapies for Myasthenia Gravis
S Alabbad, M AlGaeed, P Sikorski, HJ Kaminski - Biodrugs, 2020 - ncbi.nlm.nih.gov
Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder that produces disabling
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
[引用][C] Monoclonal Antibody-Based Therapies for Myasthenia Gravis
S Alabbad, M AlGaeed, P Sikorski, HJ Kaminski - BioDrugs, 2020 - cir.nii.ac.jp
Monoclonal Antibody-Based Therapies for Myasthenia Gravis | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
Monoclonal Antibody-Based Therapies for Myasthenia Gravis
S Alabbad, M AlGaeed, P Sikorski… - …, 2020 - hsrc.himmelfarb.gwu.edu
Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder that produces disabling
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …